Pharvaris N.V. (PHVS) Stock Ticker
PHVS right now
Market factors today
Unlock the full PHVS picture
About Pharvaris N.V.
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.
PHVS stock facts
| Ticker symbol | PHVS |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $2.2B |
| CEO | Berndt Modig |
| Employees | 148 |
| Headquarters | Zug, ZH, CH |
| IPO date | 2021-02-04 |
| Website | pharvaris.com |
What you can see for PHVS on Tickr
Live PHVS price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the PHVS report.
Rankings
FAQ
What is the ticker symbol for Pharvaris N.V.?
The ticker symbol for Pharvaris N.V. is PHVS, listed on the NASDAQ.
What is PHVS?
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and…